Dossier assessment

Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-24
Last updated

Report documents

  1. Extract of dossier assessment

    Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 361 kB, EN, not accessible
  2. Dossier assessment

    Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible

Press releases

Romosozumab in osteoporosis: considerable added benefit for women after menopause

Fewer vertebral fractures and fewer other typical fractures in postmenopausal women with severe osteoporosis at high risk of fracture

Additional information

Federal Joint Committee (G-BA)

2020-09-03 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-24
Commission
Commission awarded on 11.03.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Addendum

    Romosozumab (osteoporosis) - Addendum to Commission A20-24

    Project no.
    A20-67
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form